SCHEMBL522797

SCHEMBL522797

CC(O)C1CC[N]CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL127724 0.78
SCHEMBL5444346 0.78
SCHEMBL240851 0.78 ALDH1A1 (0.36)
SCHEMBL342675 0.78
SCHEMBL239991 0.77
SCHEMBL7519105 0.74 TP53 (0.34)
SCHEMBL16231365 0.73
SCHEMBL9559082 0.73 TP53 (0.36)
SCHEMBL30153374 0.73
SCHEMBL10964 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117510561-A Tylosin derivative and preparation method and application thereof 中国农业科学院饲料研究所 2024-02-06 CN claimed
US-11234987-B2 Isoxazole compounds as inhibitors of heat shock proteins CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2022-02-01 US claimed
US-10413550-B2 Isoxazole compounds as inhibitors of heat shock proteins THE INSTITUTE OF CANCER RESEARCH (GB) 2019-09-17 US claimed
US-9718793-B2 Isoxazole compounds as inhibitors of heat shock proteins VERNALIS (R&D) LTD. (GB) 2017-08-01 US claimed
US-20170049781-A1 HSP90 INHIBITOR COMBINATIONS NOVARTIS AG (CH) 2017-02-23 US claimed
US-20150209362-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR NOVARTIS AG (CH) 2015-07-30 US claimed
US-20140328834-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR NOVARTIS AG (CH) 2014-11-06 US claimed
US-20140242088-A1 Hsp90 inhibitor combinations NOVARTIS AG (CH) 2014-08-28 US claimed
US-8507480-B2 Isoxazole compounds as inhibitors of heat shock proteins VERNALIS (R&D) LIMITED (GB) 2013-08-13 US claimed
US-8450310-B2 Isoxazole compounds as inhibitors of heat shock proteins VERNALIS (R&D) LIMITED (GB) 2013-05-28 US claimed
US-6967216-B2 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor ASTRAZENECA AB (SE) 2005-11-22 US claimed
WO-2004072051-A1 ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS VERNALIS (CAMBRIDGE) LIMITED (GB) 2004-08-26 WO claimed
WO-2003104233-A1 4,5-DIHYDRO-IMIDAZO (4,5,1-IJ) QUINOLIN-6-ONES DERIVATIVES AND THEIR USE AS POLY (ADP-RIBOSYL) TRANSFERASE (PARP) INHIBITORS ALTANA PHARMA AG (DE) 2003-12-18 WO claimed
US-20030225097-A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor ASTRAZENECA AB (SE) 2003-12-04 US claimed
EP-1278739-A1 AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR AstraZeneca AB (SE) 2003-01-29 EP claimed
EP-0765865-B1 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION SEIKAGAKU KOGYO CO LTD (JP) 2001-12-12 EP claimed
WO-2001085714-A1 AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR ASTRAZENECA AB (SE) 2001-11-15 WO claimed
WO-1998025885-A1 ANTHRAQUINONES WITH BIOLOGICAL ACTIVITY CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1998-06-18 WO claimed
US-5763438-A ANTIVIRAL AGENTS SEIKAGAKU CORPORATION (JP) 1998-06-09 US claimed
EP-0765865-A1 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION SEIKAGAKU CORPORATION (JP) 1997-04-02 EP claimed